12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brilinta ticagrelor regulatory update

AstraZeneca submitted an MAA to EMEA for Brilinta to prevent cardiovascular events in acute coronary syndrome (ACS) patients. The pharma also plans to...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >